Statins, Caloric Restriction and Longevinex® in a One-eyed Patient with Macular Drusen

September 2018

Anish Bhandari1*, Mansi Katkar1, Stuart Richer2 and William Stiles3

1 Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago,IL 60064, USA.
2 Chicago Medical School, Rosalind Franklin University of Medicine and Science, Family & Preventive Medicine, Captain James A Lovell Federal Health Care Center, North Chicago, IL 60064, USA.
3 Captain James A Lovell Federal Health Care Center, North Chicago, IL 60064, USA

ABSTRACT

Aims: Evaluate the effects of Longevinex®, Statins, and caloric restriction in a one-eyed patient with Dominant Drusen.

Presentation of Case: A 44-year old male patient with OD congenital amblyopia (20/800 VA) and persistent OS confluent drusen (20/20 VA) (Dominant Drusen) was prescribed AREDS I supplementation for 13 years, with stabile vision and retinal exams. Subsequently, the patient developed worrisome OS Amsler grid distortion along with OS sub-retinal drusenoid deposits (SDD) and retinal architecture disruption.

Discussion: A significant increase in the drusen-free macular area (DFMA) of the patient occurred following 2 years of statin drugs and weight reduction and 4 years daily intake of a caloric restriction mimetic nutrient capsule. Only the Longevinex® red wine matrix nutrient complex resulted in complete Amsler grid resolution and sustainable normalisation of his retinal SD-OCT architecture.

Conclusion: This case provides a longitudinal perspective on a novel therapy for SDD amelioration with promising results. Within the context of previously published research on Longevinex®, this approach potentially provides an efficient, cost effective, and compassionate strategy for patients at risk for AMD as well.

Read full paper here >>